Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint Infection

NCT ID: NCT01144000

Last Updated: 2012-06-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2016-06-30

Brief Summary

To determine the outcome and safety of a combined antimicrobial treatment involving daptomycin and surgical approach involving retention or short-interval two-stage exchange of the implant. Patients with hip, knee and shoulder Prosthetic Joint Infection (PJI) caused by methicillin-susceptible and methicillin-resistant staphylococci will be included and followed during 2 years.

Detailed Description

In this prospective open observational clinical study (phase 2) patients with hip, knee and shoulder PJI (as defined below) caused by methicillin-susceptible and methicillin-resistant staphylococci will be included. An informed consent will be obtained prior to patient inclusion. Medical records will be prospectively abstracted for demographic characteristics, clinical, radiographic, laboratory and microbiologic data using a standardized case report form (CRF). After inclusion, intravenous daptomycin 10 mg/kg (calculated as actual body weight) is given once daily for 2-3 weeks, followed by oral rifampin-containing antibiotics for a total of 3 months (as outlined below).

Two surgical modalities will be applied according to the PJI treatment algorithm:

• Open debridement and retention of the prosthesis (change of mobile parts): daptomycin will be combined with rifampin.
• Two-stage exchange of the prosthesis with a short interval (2-3 weeks): daptomycin of the prosthesis: daptomycin will be used alone.

The decision whether the implant will be retained or removed is based on objective criteria of the treatment algorithm and is not subject to bias. All consecutive patients with a staphylococcal PJI infection of the hip, knee or shoulder prosthesis will be included, if no exclusion criterion is present, obviating the selection bias. Since not many specialized institutions are treating patients with PJI, we expect low number of patients.

Conditions

Staphylococcal Infections

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Daptomycin

High dose Daptomycin in hip, knee and shoulder prosthesis infections

Group Type: EXPERIMENTAL

Daptomycin

Intervention Type: DRUG

10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)

Interventions

Daptomycin

10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)

Intervention Type: DRUG

Other Intervention Names

Cubicin

Eligibility Criteria

Inclusion Criteria

1. Informed consent has been obtained;

2. Subject is 18-80 years of age;

3. Subject has a PJI of the hip, knee and shoulder prosthesis caused by Staphylococcus aureus or coagulase-negative staphylococci (CNS) susceptible to daptomycin and rifampin;

4. Surgical approach: Debridement and retention of the prosthesis OR a two-stage prosthesis exchange with a short interval (2-3 weeks). The selection of the surgical procedure is performed according to the PJI treatment algorithm;

5. Subject is willing to participate in the study, to follow protocol study treatment regimen, and to comply with all planned follow-up assessments;

6. Females of childbearing potential are willing to practice reliable birth control measures other than oral contraceptives (e.g., condoms or diaphragms together with a spermicidal foam or gel) and willing to undergo a urine pregnancy test prior to study entry.

Exclusion Criteria

1. Significant renal insufficiency (creatinine clearance rate ≤30 ml/min, as determined by the Cockcroft-Gault equation at inclusion);

2. Significant hepatic dysfunction at inclusion (AST or ALT ≥4 x upper limit of normal value);

3. Elevated creatin phosphokinase (CPK) ≥2 x upper limit of normal value at inclusion

4. PJI caused by additional microorganism;

5. Non-adherence to the PJI treatment algorithm (see below);

6. Subject has been previously enrolled in the study or is currently enrolled in another investigational study previously enrolled in the study or is currently enrolled in another investigational study, which deviates from the treatment algorithm;

7. Subject had prior exposure to daptomycin within the past 3 months;

8. Allergy or intolerance to daptomycin or rifampin, known hypersensitivity;

9. Body mass index (BMI) >45 kg/m²;

10. Subject is pregnant, nursing or lactating;

11. Inability to read and understand the participant's information.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Lausanne Hospitals

OTHER

Sponsor Role: collaborator

Kantonsspital Liestal

OTHER

Sponsor Role: collaborator

Schulthess Klinik

OTHER

Sponsor Role: collaborator

Andrej Trampuz

OTHER

Sponsor Role: lead

Responsible Party

Andrej Trampuz

Dr. med.

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Andrej Trampuz

Role: PRINCIPAL_INVESTIGATOR

Centre hospitaliere universitaire vaudvoise (CHUV) University Hospital of Lausanne

Locations

Centre hospitaliere universitaire vaudois (CHUV)

Lausanne, Canton of Vaud, Switzerland

Kantonsspital

Liestal, , Switzerland

Schulhess Clinic

Zurich, , Switzerland

Countries

Switzerland

Central Contacts

Andrej Trampuz, MD

Role: CONTACT

andrej.trampuz@chuv.ch

+41 21 314 3992

Facility Contacts

Andrej Trampuz

Role: primary

andrej.trampuz@chuv.ch

+41 (0)21 314 39 92

Werner Zimmerli, MD

Role: primary

werner.zimmerli@ksli.ch

+41 61 925 1111

Martin Clauss, MD

Role: backup

martin.clauss@ksli.ch

Markus Vogt, MD

Role: primary

markus.vogt@zgks.ch

Other Identifiers

CCBC134ACH03T

Identifier Type: -

Identifier Source: org_study_id